Novo Nordisk increases sales of diabetes products

Despite downward pressure on insulin prices in the US, Novo Nordisk was able to increase group sales in the first half year of this year on the strength of its new generation insulins and Victoza, its glucagon-like peptide-1 (GLP-1) drug for Type 2 diabetes.

Full text available to subscribers only. Click here for information on subscribing to MedNous.